Sangamo Therapeutics

SGMO · NASDAQ

$0.11+$0.0088 (+8.70%)TodayMarket closed · Oct 20, 3:59 PM ET

Prev close $0.1012

Latest news

NewsJun 23, 1:46 PM ETVandana Singh
Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle
NewsJun 12, 2:40 PM ETCaroline Ryan
Deal Dispatch: Carlyle Buys Chung Ho Group, Second Nature Brands Acquires Tillamook Country Smoker, GoHealth Bankruptcy
Press releaseJun 1, 8:30 AM ETGlobe Newswire
How Advanced Drug Delivery Could Improve Existing Cancer Treatments
NewsMay 14, 5:00 PM ET
Full Transcript: Sangamo Therapeutics Q1 2026 Earnings Call
NewsMay 14, 7:11 AM ET
Earnings Scheduled For May 14, 2026
Press releaseMay 11, 4:05 PM ETGlobe Newswire
Sangamo Therapeutics Announces First Quarter 2026 Earnings Call
NewsMay 4, 5:06 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
NewsMay 1, 5:05 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
Press releaseApr 30, 8:05 AM ETGlobe Newswire
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)
NewsApr 29, 1:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsApr 29, 12:19 PM ETAvi Kapoor
Crude Oil Jumps 5%; Automatic Data Processing Posts Upbeat Earnings
NewsApr 29, 9:43 AM ETAvi Kapoor
Dow Falls 100 Points; Brinker Earnings Beat Estimates
Press releaseApr 29, 8:05 AM ETGlobe Newswire
Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market
NewsMar 31, 1:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsMar 31, 8:05 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsMar 30, 5:05 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
Press releaseMar 30, 4:01 PM ETGlobe Newswire
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results
Press releaseMar 9, 8:05 AM ETGlobe Newswire
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
Press releaseFeb 3, 4:05 PM ETGlobe Newswire
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
NewsFeb 3, 12:05 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
Press releaseDec 18, 8:05 AM ETGlobe Newswire
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
Press releaseDec 2, 8:05 AM ETGlobe Newswire
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
NewsNov 21, 12:05 PM ET
12 Health Care Stocks Moving In Friday's Intraday Session
NewsNov 10, 4:07 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
NewsNov 6, 6:12 AM ET
Earnings Scheduled For November 6, 2025
NewsAug 4, 12:40 PM ET
'South Africa, Gates Foundation Pledge Funds to Sustain HIV Research After US Cuts' - Bloomberg News
Press releaseJun 24, 8:05 AM ETBusiness Wire
Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
NewsMay 13, 1:06 PM ET
12 Health Care Stocks Moving In Tuesday's Intraday Session
NewsMay 13, 8:10 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsMay 13, 5:45 AM ETRishabh Mishra
US Stocks Likely To Open Lower After A Strong Rally: 'Lows Are Likely In And Better Times Are Coming,' Says Expert
NewsMay 13, 5:28 AM ETAvi Kapoor
Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Press releaseMay 12, 6:26 PM ETBusiness Wire
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
Press releaseMay 12, 6:23 PM ETBusiness Wire
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
NewsMay 12, 5:06 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
Press releaseMay 12, 4:00 PM ETBusiness Wire
Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day
Press releaseMay 6, 4:35 PM ETBusiness Wire
Sangamo Therapeutics Announces First Quarter 2025 Earnings Call
Press releaseMay 6, 8:30 AM ETBusiness Wire
Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease
Press releaseApr 28, 4:31 PM ETBusiness Wire
Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
NewsApr 3, 10:26 PM ETShivdeep Dhaliwal
RH, Five Below, Sangamo, Bank Of America, Tesla: Why These 5 Stocks Are On Investors' Radars Amid Trump Tariff Meltdown (CORRECTED)
Press releaseApr 3, 4:01 PM ETBusiness Wire
Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System
NewsMar 18, 4:00 PM ET
8 Analysts Assess Sangamo Therapeutics: What You Need To Know
NewsMar 18, 6:16 AM ETRishabh Mishra
US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle

Deal Dispatch: Carlyle Buys Chung Ho Group, Second Nature Brands Acquires Tillamook Country Smoker, GoHealth Bankruptcy

How Advanced Drug Delivery Could Improve Existing Cancer Treatments

Full Transcript: Sangamo Therapeutics Q1 2026 Earnings Call

Earnings Scheduled For May 14, 2026

Sangamo Therapeutics Announces First Quarter 2026 Earnings Call

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Friday's After-Market Session

Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

12 Health Care Stocks Moving In Wednesday's Intraday Session

Crude Oil Jumps 5%; Automatic Data Processing Posts Upbeat Earnings

Dow Falls 100 Points; Brinker Earnings Beat Estimates

Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results

Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026

12 Health Care Stocks Moving In Tuesday's Intraday Session

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Monday's After-Market Session

Earnings Scheduled For November 6, 2025

'South Africa, Gates Foundation Pledge Funds to Sustain HIV Research After US Cuts' - Bloomberg News

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

US Stocks Likely To Open Lower After A Strong Rally: 'Lows Are Likely In And Better Times Are Coming,' Says Expert

Why Coinbase Global Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

12 Health Care Stocks Moving In Monday's After-Market Session

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

RH, Five Below, Sangamo, Bank Of America, Tesla: Why These 5 Stocks Are On Investors' Radars Amid Trump Tariff Meltdown (CORRECTED)

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System

8 Analysts Assess Sangamo Therapeutics: What You Need To Know

US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'